Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy

Francisco Leyva; Abbasin Zegard; Kiran Patel; Jonathan Panting; Howard Marshall; Tian Qiu

doi:10.1111/pace.13287

Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy

Francisco Leyva, Abbasin Zegard, Kiran Patel, Jonathan Panting, Howard Marshall, Tian Qiu

Aston Medical School

Research output: Contribution to journal › Article

Abstract

Background and Aims: Right ventricular pacing may lead to heart failure (HF). Upgrades from pacemakers to cardiac resynchronization therapy (CRT) were excluded from most randomized, controlled trials. We sought to determine the long-term outcomes of upgrading from pacemakers to CRT with (CRT-D) or without (CRT-P) defibrillation in patients with no history of sustained ventricular arrhythmias.

Methods and Results: In this observational study, clinical events were quantified in relation to the type of implant (de novo or upgrade) and device type at upgrade (CRT-P or CRT-D). Patients underwent CRT implantation (n = 1,545; 1,314 [85%] de novo implants and 231 [15%] upgrades) over a median of 4.6 years [interquartile range: 2.4 - 7.0]). In analyses of crude event rates, upgrades had a higher total mortality (adjusted hazard ratio [aHR]: 1.33; 95% confidence interval [CI] 0.10-1.61), a higher total mortality or HF hospitalization (aHR: 1.26; 95% CI 1.05-1.51), but similar mortality or hospitalization for major adverse cardiac events (MACEs, aHR: 1.15; 95% CI 0.96-1.38). No group differences emerged in any of these endpoints after propensity score matching. After inverse probability weighting in upgrades, total mortality (HR: 0.55; 95% CI 0.36-0.73), total mortality or HF hospitalization (HR: 0.56; 95% CI 0.34-0.79) and total mortality or hospitalization for MACEs (HR: 0.61; 95% CI 0.40-0.82) were lower after CRT-D than after CRT-P.

Conclusion: Upgrading from pacemakers to CRT was associated with a similar long-term risk of mortality and morbidity to de novo CRT. After upgrade, CRT-D was CRT-D was associated with lower mortality than CRT-P

Original language	English
Pages (from-to)	290-298
Journal	Pacing and Clinical Electrophysiology
Volume	41
Issue number	3
Early online date	25 Jan 2018
DOIs	https://doi.org/10.1111/pace.13287
Publication status	Published - 8 Mar 2018

Bibliographical note

Copyright: 2018 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Funding: Boston Scientific

Keywords

cardiac resynchronization therapy
pacemakers
implantable cardioverter defibrillators
device upgrade

Access to Document

10.1111/pace.13287Licence: CC BY

Clinical Outcomes After Upgrading from Pacemakers
Copyright: 2018 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Final published version, 422 KBLicence: CC BY-NC

http://onlinelibrary.wiley.com/doi/10.1111/pace.13287/abstract

Fingerprint Dive into the research topics of 'Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy'. Together they form a unique fingerprint.

Cite this

Leyva, F., Zegard, A., Patel, K., Panting, J., Marshall, H., & Qiu, T. (2018). Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy. Pacing and Clinical Electrophysiology, 41(3), 290-298. https://doi.org/10.1111/pace.13287

@article{5af32d284ef24a6d889d018428662bcc,

title = "Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy",

abstract = "Background and Aims: Right ventricular pacing may lead to heart failure (HF). Upgrades from pacemakers to cardiac resynchronization therapy (CRT) were excluded from most randomized, controlled trials. We sought to determine the long-term outcomes of upgrading from pacemakers to CRT with (CRT-D) or without (CRT-P) defibrillation in patients with no history of sustained ventricular arrhythmias. Methods and Results: In this observational study, clinical events were quantified in relation to the type of implant (de novo or upgrade) and device type at upgrade (CRT-P or CRT-D). Patients underwent CRT implantation (n = 1,545; 1,314 [85%] de novo implants and 231 [15%] upgrades) over a median of 4.6 years [interquartile range: 2.4 - 7.0]). In analyses of crude event rates, upgrades had a higher total mortality (adjusted hazard ratio [aHR]: 1.33; 95% confidence interval [CI] 0.10-1.61), a higher total mortality or HF hospitalization (aHR: 1.26; 95% CI 1.05-1.51), but similar mortality or hospitalization for major adverse cardiac events (MACEs, aHR: 1.15; 95% CI 0.96-1.38). No group differences emerged in any of these endpoints after propensity score matching. After inverse probability weighting in upgrades, total mortality (HR: 0.55; 95% CI 0.36-0.73), total mortality or HF hospitalization (HR: 0.56; 95% CI 0.34-0.79) and total mortality or hospitalization for MACEs (HR: 0.61; 95% CI 0.40-0.82) were lower after CRT-D than after CRT-P. Conclusion: Upgrading from pacemakers to CRT was associated with a similar long-term risk of mortality and morbidity to de novo CRT. After upgrade, CRT-D was CRT-D was associated with lower mortality than CRT-P",

keywords = "cardiac resynchronization therapy, pacemakers, implantable cardioverter defibrillators, device upgrade ",

author = "Francisco Leyva and Abbasin Zegard and Kiran Patel and Jonathan Panting and Howard Marshall and Tian Qiu",

note = "Copyright: 2018 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Funding: Boston Scientific",

year = "2018",

month = mar,

day = "8",

doi = "10.1111/pace.13287",

language = "English",

volume = "41",

pages = "290--298",

journal = "Pacing and Clinical Electrophysiology",

issn = "0147-8389",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Clinical outcomes after upgrading from pacemakers to cardiac resynchronization therapy

AU - Leyva, Francisco

AU - Zegard, Abbasin

AU - Patel, Kiran

AU - Panting, Jonathan

AU - Marshall, Howard

AU - Qiu, Tian

N1 - Copyright: 2018 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. Funding: Boston Scientific

PY - 2018/3/8

Y1 - 2018/3/8

N2 - Background and Aims: Right ventricular pacing may lead to heart failure (HF). Upgrades from pacemakers to cardiac resynchronization therapy (CRT) were excluded from most randomized, controlled trials. We sought to determine the long-term outcomes of upgrading from pacemakers to CRT with (CRT-D) or without (CRT-P) defibrillation in patients with no history of sustained ventricular arrhythmias. Methods and Results: In this observational study, clinical events were quantified in relation to the type of implant (de novo or upgrade) and device type at upgrade (CRT-P or CRT-D). Patients underwent CRT implantation (n = 1,545; 1,314 [85%] de novo implants and 231 [15%] upgrades) over a median of 4.6 years [interquartile range: 2.4 - 7.0]). In analyses of crude event rates, upgrades had a higher total mortality (adjusted hazard ratio [aHR]: 1.33; 95% confidence interval [CI] 0.10-1.61), a higher total mortality or HF hospitalization (aHR: 1.26; 95% CI 1.05-1.51), but similar mortality or hospitalization for major adverse cardiac events (MACEs, aHR: 1.15; 95% CI 0.96-1.38). No group differences emerged in any of these endpoints after propensity score matching. After inverse probability weighting in upgrades, total mortality (HR: 0.55; 95% CI 0.36-0.73), total mortality or HF hospitalization (HR: 0.56; 95% CI 0.34-0.79) and total mortality or hospitalization for MACEs (HR: 0.61; 95% CI 0.40-0.82) were lower after CRT-D than after CRT-P. Conclusion: Upgrading from pacemakers to CRT was associated with a similar long-term risk of mortality and morbidity to de novo CRT. After upgrade, CRT-D was CRT-D was associated with lower mortality than CRT-P

AB - Background and Aims: Right ventricular pacing may lead to heart failure (HF). Upgrades from pacemakers to cardiac resynchronization therapy (CRT) were excluded from most randomized, controlled trials. We sought to determine the long-term outcomes of upgrading from pacemakers to CRT with (CRT-D) or without (CRT-P) defibrillation in patients with no history of sustained ventricular arrhythmias. Methods and Results: In this observational study, clinical events were quantified in relation to the type of implant (de novo or upgrade) and device type at upgrade (CRT-P or CRT-D). Patients underwent CRT implantation (n = 1,545; 1,314 [85%] de novo implants and 231 [15%] upgrades) over a median of 4.6 years [interquartile range: 2.4 - 7.0]). In analyses of crude event rates, upgrades had a higher total mortality (adjusted hazard ratio [aHR]: 1.33; 95% confidence interval [CI] 0.10-1.61), a higher total mortality or HF hospitalization (aHR: 1.26; 95% CI 1.05-1.51), but similar mortality or hospitalization for major adverse cardiac events (MACEs, aHR: 1.15; 95% CI 0.96-1.38). No group differences emerged in any of these endpoints after propensity score matching. After inverse probability weighting in upgrades, total mortality (HR: 0.55; 95% CI 0.36-0.73), total mortality or HF hospitalization (HR: 0.56; 95% CI 0.34-0.79) and total mortality or hospitalization for MACEs (HR: 0.61; 95% CI 0.40-0.82) were lower after CRT-D than after CRT-P. Conclusion: Upgrading from pacemakers to CRT was associated with a similar long-term risk of mortality and morbidity to de novo CRT. After upgrade, CRT-D was CRT-D was associated with lower mortality than CRT-P

KW - cardiac resynchronization therapy

KW - pacemakers

KW - implantable cardioverter defibrillators

KW - device upgrade

UR - http://onlinelibrary.wiley.com/doi/10.1111/pace.13287/abstract

U2 - 10.1111/pace.13287

DO - 10.1111/pace.13287

M3 - Article

VL - 41

SP - 290

EP - 298

JO - Pacing and Clinical Electrophysiology

JF - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 3

ER -